Multi-platform molecular profiling increases the median overall survival of those who receive treatment with clinical benefit by 422 days from time of profiling.
Study demonstrates Next-Generation Sequencing can determine microsatellite instability status among cancer types, identifies subset of patients who may benefit from immunotherapy.
Caris’s biomarker driven therapy demonstrates clinical benefit for nearly 30% of patients with difficult-to-treat metastatic gastric and oesophageal cancer.
Pilot study shows applicability of Caris Molecular Intelligence to improve patient outcomes in clinical practice.
Caris Molecular Intelligence has the highest clinical utility and is improving patient outcomes in clinical practice.
Comparison of four commercially available tumour profiling services highlights superiority of Caris Molecular Intelligence.
Patients with rare and heavily pretreated solid tumours show significant clinical benefit after Caris Molecular Intelligence-guided treatment.
Findings from a new clinical appraisal of molecular profiling for clinical decision making in advanced cancer.
Improvement in overall survival for patients with advanced ovarian cancer treated matching Caris Molecular Intelligence profiling recommendations.